Inflammatory Bowel Disease Treatment Market Size To Be Reached
Dallas, March 11, 2022 (GLOBE NEWSWIRE) — According to a report published by The Brainy Insights, the global inflammatory bowel disease treatment market is expected to grow from $18.47 billion in 2020 to $28.96 billion by by 2030, at a CAGR of 4.6% over the forecast period 2021-2030.
Inflammatory bowel disease (IBD) is a term for diseases involving chronic inflammation of the digestive tract. Some common symptoms of IBD are: abdominal pain, weight loss, persistent diarrhea, rectal bleeding, and fatigue. Ulcerative colitis and Crohn’s disease are the two most common types of IBD. The colon or large intestine are the only parts of the body affected by ulcerative colitis. On the other hand, Crohn’s disease can affect any part of the gastrointestinal tract, from the mouth to the anus. The last part of the small intestine or the colon, or both, are the areas most often affected. Anti-inflammatories are frequently used as the first line of treatment for inflammatory bowel disease. Additionally, immune system suppressors suppress the immune response, which sends inflammation-inducing chemicals through the body, in a variety of ways.
Request a sample to get authentic analysis and complete market insights @ https://www.thebrainyinsights.com/enquiry/sample-request/12607
The major players operating in the global inflammatory bowel disease treatment market are Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc, Alkem Laboratories Limited, Allergan plc, B&W Tek, Biogen Inc., Celgene Corporation, Celltrion Healthcare, Cosmo Pharmaceuticals, Gilead Sciences, Innovate Biopharmaceuticals, Janssen Biotech Inc., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., PG Instruments Limited, Takeda Pharmaceutical Company Limited, UCB Inc and Valeant Pharmaceuticals International, among others. To improve their position in the global Inflammatory Bowel Disease Treatment market, the major players are now focusing on adopting strategies such as product innovations, mergers and acquisitions, recent developments, joint ventures, collaborations and partnerships.
The ulcerative colitis segment is expected to expand significantly over the projected period.
The type segment is divided into ulcerative colitis, crohn’s disease. Due to the large patient population and increasing approval of biologics for the treatment of ulcerative colitis, the ulcerative colitis segment is expected to grow significantly over the projected period. Additionally, the use of biologics to treat ulcerative colitis is expected to increase in the coming years.
Learn more about analyzing reports with numbers and data tables, as well as the table of contents. Ask an Analyst @ https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12607
The TNF inhibitors segment led the market with a market share of around 48% and a market value of around USD 8.87 billion in 2020.
The Drug Classes segment includes Corticosteroids, Aminosalicylates, JAK Inhibitors, TNF Inhibitors, Anti-integrins, IL Inhibitors, etc. The TNF inhibitors segment led the market with a market share of around 48% and a market value of around USD 8.87 billion in 2020. The TNF inhibitors segment led the market with a share of market around 48% in 2020. Anti-integrins, corticosteroids, aminosalicylates all hold a considerable market share in the treatment of inflammatory bowel diseases. Aminosalicylates are the first-line treatment for IBD. JAK inhibitors, on the other hand, are expected to grow at the fastest rate over the forecast period.
The hospital pharmacy segment led the market with a market share of 44% and a market value of USD 8.13 billion in 2020.
By distribution channel, the market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market with a market share of 44% and a market value of USD 8.13 billion in 2020. During the forecast period, the segment is expected to dominate the market.
Contact Sales for further assistance with purchasing this report @ https://www.thebrainyinsights.com/buy-now/12607/single
Regional Segment Analysis of Inflammatory Bowel Disease Treatment Market
• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, rest of APAC)
• South America (Brazil and rest of South America)
• Middle East and Africa (UAE, South Africa, Rest of MEA)
During the forecast period, the Asia-Pacific inflammatory bowel disease treatment market is expected to grow at the fastest rate. Over the next few years, the market is likely to be driven by the growing prevalence of Crohn’s disease and ulcerative colitis in the region, increasing prescription of biosimilars, and increasing approval of new drugs. According to a study published in NCBI, men had a higher prevalence of Crohn’s disease than women. Inflammatory bowel disease is most common in East Asia, which includes Japan, Korea, China, and other countries. Furthermore, the growth of the market is expected to be aided by the economic growth of countries like India and China.
About the report:
The global inflammatory bowel disease treatment market is analyzed on the basis of value (Billion USD). All segments have been analyzed on a global, regional and country basis. The study includes analysis of more than 30 countries for each segment. The report offers an in-depth analysis of the drivers, opportunities, restraints and challenges to obtain key market insights. The study includes Porter’s Five Forces Model, Attractiveness Analysis, Commodity Analysis, Supply, Demand Analysis, Competitor Position Grid Analysis, analysis of distribution and marketing channels.
We offer custom solutions to meet your needs, request customization @ https://www.thebrainyinsights.com/enquiry/request-customization/12607
About The Brainy Insights:
The Brainy Insights is a market research company, aiming to provide businesses with actionable insights through data analytics to improve their business acumen. We have a robust forecasting and estimating model to meet customers’ high-quality production goals in a short period of time. We provide custom (customer specific) and syndicated reports. Our union reporting repository is diverse across all domain categories and subcategories. Our customized solutions are designed to meet customer requirements, whether they are looking to expand or planning to launch a new product in the global market.
Business Development Manager
Email: [email protected]